Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission
Gisela Piñero; Míriam Mañosa; Margalida Calafat; Eva Vayreda; Fiorella Cañete; Maria Puig; Eugeni Domènech;
Gastroenterol Hepatol. 2024;47:612-9
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis
Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;
Gastroenterol Hepatol. 2024;47:522-52
Treat-to-target approach in the management of inflammatory Bowel disease
Paulina Nuñez F; Uma Mahadevan; Rodrigo Quera; Constanza Bay; Patricio Ibañez;
Gastroenterol Hepatol. 2021;44:312-9